Mucin 20 modulates proteasome capacity through c‐Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma

Mantle cell lymphoma (MCL) is a haematologic malignancy. The proteasome inhibitor (PI) bortezomib has been approved to treat MCL, but resistance has emerged through mechanisms that remain unclear. This study aimed to explore the mechanism of PI resistance in MCL and identify new targets for this pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaobin, Shirazi, Fazal, Yan, Wei, Liu, Xiaoyu, Wang, Hua, Orlowski, Robert Z., Wang, Huihan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572801/
https://www.ncbi.nlm.nih.gov/pubmed/34651428
http://dx.doi.org/10.1111/jcmm.16953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572801/
https://www.ncbi.nlm.nih.gov/pubmed/34651428
http://dx.doi.org/10.1111/jcmm.16953

Ejemplares similares